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Abstract
Previous studies of the HIV-1 disease have shown that HLA and Chemokine receptor genetic variants influence disease
progression and early viral load. We performed a Genome Wide Association study in a cohort of 605 HIV-1-infected
seroconverters for detection of novel genetic factors that influence plasma HIV-RNA and cellular HIV-DNA levels. Most of the
SNPs strongly associated with HIV-RNA levels were localised in the 6p21 major histocompatibility complex (MHC) region and
were in the vicinity of class I and III genes. Moreover, protective alleles for four disease-associated SNPs in the MHC locus
(rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV
controllers. Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four
SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2
genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene). Our data provide evidence that the MHC controls both
HIV replication and HIV reservoir. They also indicate that two additional genomic loci may influence the HIV reservoir.
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Introduction
In the past ten years, candidate gene approaches were used to
investigate host genetic variability in HIV-1 disease. Chemokine
receptors such as CCR5 and CCR2 [1] and Major Histocompatibility
Complex (MHC) class I genetic variation have been definitively
associated with either clinical disease progression or HIV-RNA levels
[2,3]. Recent advances in large-scale genotyping technologies enabled
genome-wide association (GWA) strategies for detection of novel
genetic variants that influence HIV-1 disease. In this respect, the first
GWA study in HIV-1 disease [4] identified three Single Nucleotide
Polymorphisms (SNPs): two of them, linked with the ability to control
plasma HIV-RNA levels, were located within the MHC region
(rs2395029 within HCP5 gene and rs9264942 near HLA-C), while a
third SNP (rs9261174), located near ZNRD1, was only associated with
disease progression. These data suggest that disease progression and
HIV-RNA might be controlled by several loci of the human genome.
Plasma HIV-RNA levels differ largely between patients. This is
the best known virological marker of HIV disease progression; its
predictive value was proven at different points of the time course of
HIV infection [5–7]. HIV-DNA levels in peripheral blood
monononuclear cells (PBMC) is another major predictive marker
for HIV disease progression representing a phenotype not yet
studied in either candidate gene or GWA approaches [8,9]. HIV-
DNA and HIV-RNA levels measure two different forms of HIV-1.
It is not clear whether HIV-DNA levels measure only the viral
reservoir. Indeed both phenotypes can be determined accurately
and, even though they are correlated, they are distinct predictive
factors for HIV disease progression. Indeed plasma HIV-RNA is a
composite marker reflecting viral fitness, replicative capacity and
host control, while intracellular HIV-DNA levels reflect the
establishment of HIV reservoirs and, thereof, the effect of
numerous host proteins that may interact with the intracellular
viral lifecycle [10].
We hypothesized that genetic variants that regulate HIV-DNA
metabolism, in particular HIV latency, are different than those
involved in HIV-RNA metabolism and HIV replication. For this
purpose, we conducted a GWA study in the large ANRS PRIMO
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3907cohort of unselected HIV-1 seroconverters (observed median time
since infection: 46 days) for identifying SNPs associated with early
plasma HIV-RNA levels[11]. All 605 Caucasian subjects of this
cohort were genotyped using Illumina Sentrix Human Hap300
Beadchip containing 317,139 tagging SNPs. We selected genetic
variants having a high likelihood of being associated with plasma
HIV-RNA levels for a false discovery rate (FDR)[12] of 25%.
In order to provide additional evidence to support these selected
HIV-1 disease-related SNPs, we compared their allelic frequencies
between this reference population (PRIMO) and an independent
population of long-term HIV controllers[13]. The latter group of
patients represents less than 0.5% of the general population of
HIV-1 infected patients, and reflects an extreme phenotype
compared to the PRIMO population. HIV controllers exhibit
sustained spontaneous control of viral replication after at least 10
years of HIV infection (observed median time since HIV diagnosis
18 years). We hypothesized that true positive genetic variants
obtained from the GWA will exhibit enrichment for protective
alleles in long-term HIV controllers compared to patients from the
PRIMO population. We also studied for the first time association
signals for another viral phenotype, i.e., cellular HIV-DNA levels.
Taken together, our data redefine the regions controlling HIV-
RNA within the MHC locus and indicate an independent effect of
SNPs located nearby not only class I but also class III genes. Some
of these SNPs are associated with HIV-RNA levels from primary
infection and early seroconversion and are over-represented in
patients showing long-term spontaneous control. Most important-
ly, our data provide evidence that the MHC locus controls both
HIV replication and HIV-DNA levels while early control of
HIV-DNA levels may be under the control of two additional
genomic loci.
Results
GWA and plasma HIV1-RNA levels
A total of 308,222 SNPs on the autosomal chromosomes passed
the quality-control filters. We tested for association of genotype
and early plasma HIV-RNA levels using a linear regression model
assuming an additive genetic effect with adjustment for gender.
The calculated log10 P-values for the SNPs genotyped in the 605
patients from the PRIMO cohort are plotted in Figure 1.
The SNPs associated with plasma HIV-RNA levels and selected
for a FDR threshold of 25% are shown in Table 1; 15 SNPs were
located on Chromosome 6, 3 each in chromosomes 12 and 16,
and one on Chromosome 4. Among the 15 SNPs located in
Chromosome 6, twelve were clustered within the 6p21 region
harbouring the MHC (from 312 kb to 321 kb). The strongest
association signal was observed for the rs10484554 SNP, which is
located upstream from HLA-C. The rs10484554(T) protective
allele had frequency of 0.128 in our population. The second
highest association signal was observed for the rs2523619 SNP
which lies within the HLA-B gene which is in strong linkage
disequilibrium (r
2=0.57) with the rs10484554 SNP. The third
highest association signal obtained in the presented study was for
the rs2395029 which lies within the class I gene HCP5 with weak
linkage disequilibrium with rs10484554 (r
2=0.13) and rs2523619
(r
2=0.07). This association signal for rs2395029 replicates the
result previously reported from CHAVI [4]. Another three HLA-
C neighbouring SNPs (rs130065, rs3130467 and rs3130473)
showing strong linkage disequilibrium (r
2.0.5) and significant
effects on viral load were among the top signals.
When comparing allelic frequencies between HIV-controllers
and the PRIMO seroconverters, four SNPs located within the
Figure 1. Genome wide association (GWA) study for plasma HIV-RNA levels in the ANRS PRIMO cohort. Negative log10 (P)-values for the
score test for genome-wide association across the genome ordered from 1pter to 22qter. Adjacent chromosomes are shown in light blue and dark
blue. The spacing between SNPs does not reflect actual physical distances. The false discovery rate was calculated based on a stratified approach (by
chromosome) leading to chromosome-specific thresholds.
doi:10.1371/journal.pone.0003907.g001
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bold in Table 1), showed highly significant differences (p,10
24)
that correspond to a striking enrichment in HIV-controllers for
protective allelic variants associated with HIV-RNA levels. We
further designated them as major SNPs. Moreover, these four
major SNPs showed highly significant p values (p,10
27) in the
CHAVI study (Table 1). It should be noted that our study on the
PRIMO cohort used plasma HIV-RNA levels measured at the
time of primary infection, while the CHAVI study used viral loads
measured during the plateau phase (6 to 18 months following
seroconversion). Overall these results support the idea that these
major SNPs have an effect on viral load throughout the whole time
course of HIV disease.
The extent of linkage disequilibrium between selected SNPs
(Table 1) lying in the 6p21 area is shown in Figures 2, and Figure
S1 and Figure S2. The genomic region flanked by these SNPs
contains both MHC class I and class III genes and extends from
the PSORS1C1 gene to TNXB gene. Supplementary Figure 1 and
2 display the linkage disequilibrium data matrix (based on
HapMap CEU data) and the genes located witin this 6p21 region
(from 312 kb to 321 kb).
Among the class I genes, only HLA-C and HLA-B genes are
adjacent to SNPs associated with the control of plasma viral load
(Figure 2). It should be noted that neither the PRIMO (Table 1)
nor the CHAVI studies[4] provide evidence for association signals
with HLA class II. Among the major SNPs, the rs2395029 is in
moderate linkage disequilibrium (r
2=0.21) with the rs3093662
SNP which lies within the Tumor Necrosis Factor (TNF) gene.
The rs12198173 and rs13199524 SNPs showed moderate linkage
disequilibrium with SNP rs2395029 as well as with all the other
SNPs in the class I MHC region. Finally the rs12198173 and
rs13199524 SNPs are in nearly complete linkage disequilibrium
(r
2=0.97), are both located in the class III region of MHC and
both lie within introns of the TNXB gene. Although mutations in
the TNXB gene are responsible for the Ehlers-Danlos Syn-
drome[14,14], it is unlikely that this gene is responsible for the
observed effect in HIV-1 plasma viral load. Other neighbouring
genes, particularly C4A and C4B (which show different types of
polymorphisms such as duplications, gene recombinations,
insertions, and SNPs inducing the appearance of premature stop
codons) are located in the immediate telomeric side of TNXB and
linked both to autoimmune and infectious diseases and are
excellent candidate genes for this effect [15]. These results provide
evidence that the region encompassing the HCP5 and MIC genes
as well as the class III region encompassing TNXB and C4 genes
region both contribute to the control of HIV-RNA levels.
Box plots for HIV-RNA levels measured during primary
infection for the four major SNPs are shown in Figure 3. In
patients homozygotes for the rs2395029(T) allele, the median
value HIV-RNA was 5.09 (range: 4.48–5.70) whereas in
Figure 2. Location of the twelve selected SNPs in the MHC region (6p21) and linkage disequilibrium plot. Upper box shows an
ideogram depicting chromosome 6 and the annotated region (transparent yellow rectangle). Lower box shows the linkage disequilibrium data matrix
calculated from the European HapMap population. The colour intensity of each box is proportional to the strength of the LD property (r
2) for the
marker pair.
doi:10.1371/journal.pone.0003907.g002
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illustrating that the minor allele G is associated with lower HIV-
RNA levels. A similar trend for the minor allele G was observed
for the rs3093662. Despite a minor allelic frequency of 0.083
(rs12198173) and 0.080 (rs13199524), with few observed homo-
zygote patients for the protective alleles (A for rs12198173, T for
rs13199524), a strong reduction (2.35 log10) for the HIV-RNA
median level was observed. Both SNPs (rs12198173 and
rs13199524) were located within the TNXB gene but the two
homozygote patients also carried one favourable HLA allele such
as HLA-B27 or HLA-B57. It should be noted that the homozygote
patients for these protective alleles (rs12198173(A), rs13199524(T))
account for 4% of the HIV controllers versus 0.3% of the PRIMO
seroconverters.
Another important result of this study was the strong association
of the rs11725412 SNP located on chromosome 4 with plasma
HIV-RNA levels both in the PRIMO and HIV controller cohorts
(Table 1). Although we cannot exclude that this finding represents
a false positive signal, the p-value on the PRIMO analysis was low
(p,6610
26) and a significant (p,6.58610
24) enrichment was
observed in HIV-controllers. The rs11725412 SNP lies in an
intergenic region in 4p14, its immediate functional neighbours are
the TBC1D1 gene (telomeric) and the KLF3 gene (centromeric).
TBC1D1, the founding member of a family of proteins sharing a
180 to 200 amino acid TBC domain, is presumed to have a role in
regulating cell proliferation and differentiation[16]. The KLF3
protein has a characteristic zinc finger domain and is classified in
the family of SP transcription factors but its precise function
remains unknown[17,18]. More distant genes in this region
include several Toll like receptors (TLR1,6,10) and PTTG2 (a
gene belonging to the securin family) that plays an important role
in cell division and survival[19,20].
GWA and cellular HIV-DNA levels
HIV-1 DNA levels in PBMCs are established at a very early
stage of HIV infection and are representative of the HIV
reservoir[21]. This marker showed a wide range (median=3.30
log10 copies/millions PBMC; IQR=0.76) in patients from the
PRIMO cohort; in contrast, HIV-1 DNA levels were very low
(median=1.77 log copies/millions PBMC; IQR=0.64) in long-
term HIV-controllers. We hypothesized that this phenotype may
be controlled by genomic regions different from those controlling
HIV replication, particularly in phases of pre-integration or in
provirus transcription that may be variable among patients.
The SNPs associated with HIV-DNA levels in the PRIMO
cohort and selected for a FDR threshold of 25% are shown in
Table 2. Among the 28 SNPs, 21 were located in the chromosome
6 (mainly in 6p21), 4 in chromosome 8, 1 in chromosome 17, 1 in
chromosome 22 and 1 in chromosome 12. Some of these hits
might represent false positives. However the four major SNPs (i.e.,
Figure 3. Boxplots for HIV-RNA levels in the PRIMO cohort for four major SNPs. Plasma HIV-RNA level is highly correlated with the
rs2395029 (HCP5), rs3093662 (TNF), rs13199524 and rs12198173 (TNXB) genotypes.
doi:10.1371/journal.pone.0003907.g003
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Table 2) previously found to be associated with HIV-RNA levels
were also associated with HIV-DNA levels. This highlights the
importance of the MHC region for both HIV replication and HIV
reservoir. The first three SNPs (with q-value ,2.3%, see Table 2)
are located within three different chromosomes, specifically
chromosomes 6, 17 and 8. The strongest association signal was
observed for the rs2395029, one of the four major SNPs associated
with plasma HIV-RNA (Table 1)[4]. The second highest
association signal corresponds to rs6503919 SNP (chromosome
17). This SNP is found in an intergenic region flanked by
DDX40[22] (which is a member of the DExH/D box family of
ATP-dependent RNA helicases) (for a recent review see[23]), and
YPEL2 (which is a putative zinc-binding protein gene)[24]. The
rs2575735 SNP (chromosome 8) lies within the SDC2 gene which
encodes for syndecan 2. Syndecan 2 is a trans HIV receptor which
binds to HIV-1 gp120 through heparan sulfate chains[25,26].
Keeping in mind that HIV controllers were selected on the basis of
a specific HIV-RNA phenotype (,400 copies/ml after 10 years of
known HIV infection), we observed no significant enrichment
(p.0.1) for the protective alleles of rs6503919 and rs2575735
SNPs in HIV controllers compared to the PRIMO patients.
Nevertheless, we cannot rule out the possibility that some of non-
chromosome 6 hits may represent false positives.
Box plots for the HIV-DNA levels in the PRIMO seroconver-
ters for the first three SNPs (rs2395029, rs6503919, and rs2575735
as listed in Table 2) are shown in figure 4. The difference in
median HIV-DNA levels between TT homozygotes and TG
heterozygous patients for rs2395029 was 20.53, illustrating that
the minor allele G is associated with lower HIV-DNA levels. A
similar trend, i.e., a 0.36 difference in median values in HIV-DNA
according to the genotype was also observed among HIV
controllers. For the SNP rs6503919 located on chromosome 17,
we observed both a 20.62 log10 difference in median HIV-DNA
values between AA and GG patients in the PRIMO cohort, and a
20.45 log10 difference in HIV controllers according to the same
genotype. A 20.62 log10 HIV-DNA difference is clinically highly
significant since it can be compared to the effect obtained within
the first year following antiretroviral treatment initiation with a
classical triple therapy[27]. For the rs2575735 SNP in chromo-
some 8, we observed a reduction of 20.37 log10 between
homozygotes AA and GG in the PRIMO patients. In contrast
such a difference was not observed in HIV controllers. This result
may imply a temporal effect which disappears over time.
Discussion
The present GWA study identified SNPs highly associated with
early viral replication in the ANRS PRIMO cohort. Although in
this study, we performed the genotyping using an Illumina 317K
chip, and gains in terms of genetic coverage and transferability[28]
could be obtained using more recent technologies it should be
Figure 4. Boxplots for HIV-DNA levels in the PRIMO cohort for the three major SNPs. Cellular HIV-DNA level is highly correlated with the
rs2395029 (HCP5), rs6503919 (intergenic DDX40 – YPEL2) and rs2575735 (SDC2) genotypes.
doi:10.1371/journal.pone.0003907.g004
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located in the MHC locus in our and Fellay’s study even that the
Fellay et al. study considered a SNP-chip having higher genetic
coverage (Illumina 550K SNP). Furthermore the definition of the
viral phenotype is different between Fellay’s study and this study;
further explaining differences in the power of associations. Four of
these SNPs exhibited a striking enrichment of their protective allele
in long-term HIV controllers as compared to the unselected
seroconverters from the PRIMO cohort. These four major SNPs
are located in the 6p21 MHC in the vicinity of class I and III genes.
The association signal observed for the rs2395029 SNP located in
the HCP5 gene, which is in complete linkage disequilibrium with
HLA-B*5701[29], replicates the previous report from the Chavi
study[4]. Interestingly, the rs2395029*T allele which has a
protective role in HIV infection was also recently shown to be
associated with increased susceptibility to psoriasis and psoriatic
arthritis[30]. One possible explanation for this MHC association
signal is that variants of the classical HLA-B and HLA-C alleles
optimally present HIV-derived peptides to CD8+ T-cells which, in
turn, kill HIV-infected cells. The results of the present study make
an additional contribution to reports in the literature regarding the
importance of HLA-B27 and HLA-B57 in long-term non-
progression and in viral load control[31–33]. Another possible
explanation relates to other MHC-related gene variants in linkage
disequilibrium with rs2395029 such as SNPs in the TNF gene. The
fact that the MICB gene is flanked by rs2395029 and rs3093662
SNPs also suggests its contribution to the control of HIV-1 RNA.
MICs are polymorphic[34,35] and affect cell-mediated cytotoxicity
through interaction with NKG2D[36,37] while TNF variants affect
numerous steps of the immune response[38]. It is, thus, possible that
HIV-infected patients who have a particular set of the classical
either HLA-B or HLA-C alleles associated with TNF and MIC
protective alleles have an increased capability to control HIV
replication during the time course of HIV disease.
In addition, the present study also highlights that some of the
major SNPs located in the MHC region have an effect on HIV-
RNA levels independently of SNP rs2395029. The two major
SNPs rs12198173 and rs13199524, which are in nearly complete
linkage disequilibrium, suggest that the class III region of MHC
plays an important role in HIV replication. In homozygote
patients for the minor allele of these SNPs, plasma HIV-RNA was
2.35 log10 lower than in patients with other genotypes. To the best
of our knowledge, the present is the first study demonstrating that
a rare genetic variant within the class III region of MHC is
associated with important viral load changes, which are compa-
rable to that obtained during the first weeks following multiple
antiretroviral therapy initiation. Undoubtedly, such an efficient
control of viral replication, both in terms of strength and duration,
provides new insights into underlying mechanisms and may lead to
novel methodologies for HIV vaccine design.
Moreover, the present study highlights the importance of SNPs
adjacent to HLA-C such as the rs10484554 which was the most
highly associated SNP in our study. HLA-C has a dual function: it
presents HIV-derived peptides to T lymphocytes but also interacts
with either activatory or inhibitory NK receptors. Unfortunately,
very few studies have focused attention on the role of HLA-C
alleles in HIV disease[39]. Recent reports[40] provided evidence
of epistatic interactions between classical HLA-B alleles and KIR-
receptor polymorphisms but again only the role of HLA-B allelic
variants was studied. It is worth noting that the protective
rs10484554*T allele was also recently shown to be associated with
increased susceptibility to psoriasis and psoriatic arthritis[30].
These findings suggest that HLA-C deserves more attention as an
HIV disease modifying gene.
The present one is the first study which explored the role of
genetic variants on the early establishment of the HIV reservoir.
Association signals for HIV-DNA levels revealed new genetic loci
that may control early steps of HIV spreading. The four major
SNPs associated with viral replication were also found to be
strongly associated with HIV-DNA levels. The strongest associa-
tion signal for HIV-DNA was again observed for the rs2395029
SNP located in the HCP5 gene suggesting that structural variants
of MHC genes also play a very important role on HIV reservoir.
Moreover, we found an association signal for the SNP
rs6503919 in chromosome 17 which lies in an intergenic region
flanked by the DDX40 and YPEL2 genes. One plausible
explanation for this finding is that the Helicase DDX40 structural
variants play an important role in the metabolism of HIV-RNA
and/or in the efficiency of provirus transcription. DEAD helicases
are generally thought to participate in many aspects of RNA
metabolism including RNA transcription, mRNA export, transla-
tion and RNA stability. It is now well established that HIV-1 has
the ability to use more than one cellular RNA helicases for its
replicative life cycle (for a recent review see [23]). The other
immediate neighbour gene of SNP rs6503919 is YPEL2, which is
a member of the zinc-binding protein family. Besides the fact that
it is associated with the mitotic apparatus, details of the exact
functions of YPEL2 are not well known to date. It is possible that
structural variants of YPEL2 affect the rate of division of immune
competent cells, thus, limiting expansion of latently infected cells
and their spreading to lymphoid tissues.
We also report an association signal on chromosome 8 for the
rs2575735 SNP lying within the Syndecan 2 gene. The role of
Syndecans (which are trans HIV receptors) on the HIV reservoir
has not been investigated to date. Syndecans play a role for HIV
dissemination to T lymphocytes and macrophages[25,26]. Our
findings support the idea that structural variants of Syndecans may
be important in controlling HIV spreading and early establishment
of the HIV reservoir. It should be noted that the protective variant
was not over-represented in long-term HIV controllers, suggesting
either a temporal effect or a lack of power due to the small number
of HIV controllers tested. It is also important to keep in mind that
the HIV controllers in the present study were selected on an HIV-
RNA based phenotype (,400 copies/ml) but not on an HIV-DNA
based phenotype. Further studies are necessary to confirm the role
of Syndecan 2 genetic variants on HIV reservoirs.
Taken together our data provide evidence that four major SNPs
in the MHC locus are associated with both control of plasma HIV-
RNA and cellular HIV-DNA levels. Most importantly they are
associated with viral load replication at the time of primary
infection, at the viral set point but also at late stages of HIV-1
disease. It is worth noting that here we performed the genotyping
using an Illumina 317K chip and that gains in terms of genetic
coverage and transferability could be obtained using more recent
technologies [28]. In our study, we provide evidence that the host
genetic control on HIV-RNA over time is under the control of
both MHC class I and class III genes. Finally, this is the first GWA
study which investigated the host determinants controlling the
HIV-1 reservoir and identified two new loci in different
chromosomes; this result implies that additional and/or different
genes than those controlling HIV replication control the
establishment of the HIV reservoir.
Materials and Methods
Patients
Since November 1996, the ongoing French ANRS PRIMO CO
06 Cohort has enrolled patients during primary HIV-1 infection in
Genetics of HIV Viral Load
PLoS ONE | www.plosone.org 8 December 2008 | Volume 3 | Issue 12 | e390781 French hospitals[11]. The present study was approved by the
Paris Cochin Ethics Committee. All subjects gave their informed
written consent. Recent infection was confirmed by one of the
following: an incomplete Western Blot pattern (absence of anti-p68
and anti p34); a detectable plasma HIV-RNA or positive p24
antigenemia a negative or weakly reactive ELISA test; an interval
less than 6 months between an authenticated negative and a
positive ELISA test. The date of infection was estimated on the
basis of one of the following: the date of symptom onset minus 15
days, the date of the incomplete Western Blot minus one month,
or the mid-point between a negative and a positive ELISA test.
The interval between the estimated date of infection and
enrolment did not exceed 6 months (median observed interval in
the cohort=46 days). Patients had to be antiretroviral-naı ¨ve at
enrolment. Clinical and biological examinations were conducted
at enrolment and at each follow-up visit, and included CD4 cell
and plasma HIV-RNA assays. Blood cells and plasma were drawn
at enrolment and at follow-up visits and frozen until analyses.
A total of 605 Caucasian patients were selected and genotyped
on the ANRS Platform; in 590 of these patients intracellular HIV-
DNA levels at enrolment were also measured. The patients were
predominantly (87.8%) males and predominantly (96.0%) infected
through sexual contact; their median age at enrolment was 34
years (IQR: 29–41).
Since May 2006, the ongoing French ANRS EP36 study has
enrolled HIV controllers, defined as patients who had more than
90% of their viral loads ,400 copies/ml after 10 years of known
HIV infection, and were disease symptom-free and antiretroviral-
therapy free. This study was approved by the Paris Bice ˆtre Ethics
Committee. Patients were identified in hospitals throughout
France, and were enrolled after written informed consent[13,41].
At enrolment, 10 ml of whole blood were collected and frozen for
further virological and genetic analyses. A total of 45 Caucasian
HIV controller patients with available DNA samples were selected
for this study.
HIV-RNA and HIV-DNA measurements
Plasma HIV-RNA levels and HIV-DNA in PBMCs used in this
paper were quantified in the first patient samples drawn at the
time of enrolment in the PRIMO cohort and the HIV controllers
study, prior to any antiretroviral therapy initiation. Median time
from infection to enrolment was 47 days IQR 37–69 HIV-RNA
and HIV-DNA levels measured during the 0–6 months following
infection predict HIV disease progression [8]. HIV-RNA levels
measured at the time of primary infection are strongly associated
with HIV-RNA levels at the set point [42].
Quantification of HIV-RNA in plasma was performed on site at
the participating hospitals, while HIV-DNA quantification was
performed at the Necker Virology laboratory using real time PCR
technology based on amplification of the HIV-1 LTR gene[43].
Briefly, after nucleic acid extraction, the total amount of DNA was
quantified. The 95% detection threshold of the assay was 5 HIV-
DNA copies/PCR, that is, 70 copies of HIV-DNA per million
PBMC when using 0.5 mg of total DNA per PCR. For HIV
controller samples, quadruplicate tests were conducted by PCR in
order to get numerical data values for very low levels. Results were
expressed as the log10 copies number per million PBMC.
Illumina SNP genotyping and quality-control filtering
The DNA samples from all patients were genotyped with
Illumina HapMap300 Beadarrays containing 317,000 SNPs. The
scanned images were processed using BeadStudio (version 3.2.23)
and all genotypes were called using the Illumina proprietary
algorithm with genotype clusters generated from the series of
samples tested.
Samples with call rate below 97% were discarded and SNPs
with Gene Call,90% were removed. SNP with either a minor
allele frequency below 0.01 or significant (p,10
27) deviation from
Hardy-Weinberg equilibrium were excluded. After applying these
filters, the average call rate across these samples was 98.3% with
308,222 SNPs on the autosomal chromosomes.
Statistical analysis
Population stratification. To detect, and control, possible
population stratification, we employed the genomic control
approach[44] using all SNPs to estimate the genomic-control
inflation factor l.
The value for l was small (l=1.005) indicating no population
substructure in our cohort and inducing no inflation of the test
statistics under the null hypothesis. We, therefore, reported all our
analyses results without regard to specific treatment for population
structure.
Multiple testing. To address the multiple testing problem,
we selected SNPs considering a 25% level for the FDR which is
the expected proportion of false discoveries among all
discoveries[12]. The q-values, which are analogous to the
adjusted P-values for the FDR criterion, measure the minimum
FDR that is incurred when calling that test significant. In the
present study, we estimated the q-values using the procedure
introduced by Dalmasso et al.[45] and considering a stratified
approach (by chromosome) as proposed by Sun et al [46].
Comparison between PRIMO and HIV controller
patients. We compared allele frequencies between the
PRIMO and HIV controller patients using an algorithm
dedicated to association studies using bi-allelic markers and
allowing fast computation of unbiased exact P-values[47].
Assessment of linkage disequilibrium between
SNPs. To assess the level of linkage disequilibrium between
SNPs, we calculated the pairwise r
2 measure between consecutive
pairs of markers throughout the genome using the expectation-
maximization algorithm to estimate 2-locus haplotype frequencies
which is implemented in the R package snpMatrix [48].
Genome wide association tests. We tested for an
association between SNPs and HIV-RNA and HIV-DNA levels
according to a linear model with an additive genetic effect with
adjustment for gender. Significance was determined using
generalized score tests [49] with SNP genotypes as the
dependent variables and either HIV-DNA or HIV-RNA levels
as the independent variables.
Supporting Information
Figure S1 Upper box: An ideogram depicting chromosome 6
and the annotated region (transparent red rectangle). Middle box:
show the SNPs with their associated -log10(P)-values, these lines
are spaced according to their actual physical location. Positions of
the four SNPs (rs2395029, rs13199524, rs12198173 and
rs3093662) are indicated on the figure. Lower box: Linkage
disequilibrium data matrix is based on HapMap CEU data.
The figure has been constructed using WGAViewer software
(http://people.genome.duke.edu/,dg48/WGAViewer/download.
php, Ge D, Zhang K, Need AC, Martin O, Fellay J, Urban TJ,
Telenti A, Goldstein DB. WGAViewer: software for genomic
annotation of whole genome association studies.Genome Res. 2008,
18:640–643).
Found at: doi:10.1371/journal.pone.0003907.s001 (0.54 MB TIF)
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log10(P)-values, these lines are spaced according to their actual
physical location. Positions of the four SNPs (rs2395029,
rs13199524, rs12198173 and rs3093662) are indicated on the
figure. Lower box shows the position of the UCSC known Genes
(June, 05 and based on UniProt, RefSeq, and GenBank mRNA)
located in the annotated region. The figure has been constructed
using Genome Browser software, Kent WJ, Sugnet CW, Furey
TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The
human genome browser at UCSC. Genome Res. 2002,12: 996–
1006).
Found at: doi:10.1371/journal.pone.0003907.s002 (0.42 MB TIF)
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